Corporate Scene

Lou Kennedy, CEO and owner

Nephron Pharmaceuticals Corporation announced a new $215 million investment and expansion in July 2020, signaling a new era of unprecedented growth, including the establishment of a vaccine production facility. Nephron’s manufacturing expansion facility stands ready to support manufacturing of vaccines, biologics, antibiotic, and chemotherapeutic drug products. The expansion includes features uniquely designed to accommodate large scale production like customized clean rooms allowing for negative or positive pressure cascades, two newly developed lines and up to six expansion lines utilizing Blow-Fill-Seal (BFS) Technology, in-line HAPA Vial Print Technology, finished goods manual and automated packaging suites, and more.
Product development and testing will be completed in the adjacent three fully equipped FDA compliant laboratories for biochemistry, chemistry, and microbiology. Each lab provides state of the art instrumentation, bright and colorful collaboration spaces, and full visibility of the research and development occurring to support the vaccination, chemotherapeutic, and antibiotic needs of our nation as those specific needs grow and evolve.